Cellebrite DI Ltd. (NASDAQ:CLBT) Stake Boosted by Juncture Wealth Strategies LLC

Juncture Wealth Strategies LLC grew its position in Cellebrite DI Ltd. (NASDAQ:CLBT) by 0.8% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 60,003 shares of the company’s stock after purchasing an additional 505 shares during the period. Juncture Wealth Strategies LLC’s holdings in Cellebrite DI were worth $1,322,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Quarry LP bought a new stake in shares of Cellebrite DI in the 3rd quarter valued at approximately $27,000. Point72 Asia Singapore Pte. Ltd. raised its holdings in Cellebrite DI by 59.6% during the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock valued at $33,000 after buying an additional 1,017 shares in the last quarter. Advisors Asset Management Inc. lifted its position in shares of Cellebrite DI by 130.5% in the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock worth $52,000 after buying an additional 1,742 shares during the last quarter. Pathway Financial Advisers LLC increased its holdings in shares of Cellebrite DI by 1,583.8% during the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock valued at $74,000 after acquiring an additional 4,118 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado acquired a new stake in Cellebrite DI in the 2nd quarter worth approximately $71,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Trading Up 1.2 %

Shares of CLBT opened at $23.70 on Friday. The stock has a fifty day moving average price of $21.29 and a two-hundred day moving average price of $18.00. Cellebrite DI Ltd. has a 52-week low of $8.73 and a 52-week high of $24.18.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.05. The business had revenue of $106.90 million for the quarter, compared to the consensus estimate of $102.06 million. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The firm’s quarterly revenue was up 27.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.09 EPS. Analysts expect that Cellebrite DI Ltd. will post 0.32 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Craig Hallum boosted their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Needham & Company LLC raised their target price on Cellebrite DI from $21.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. raised their target price on Cellebrite DI from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Monday, December 16th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $21.57.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.